<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823091</url>
  </required_header>
  <id_info>
    <org_study_id>auto-CAR7-T-cells</org_study_id>
    <nct_id>NCT04823091</nct_id>
  </id_info>
  <brief_title>Autologous Cells Derived Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies</brief_title>
  <official_title>Safety and Efficacy of Autologous Cells Derived Anti-CD7 CAR-Engineered T Cells for Relapsed/Refractory T Lymphoid Malignancies: a Single-center, Open- Label, Non-randomized, Single-arm Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing GoBroad Hospital Management Co.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai YaKe Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, single-arm study to evaluate the primary safety and&#xD;
      efficacy of autologous anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in&#xD;
      patients with relapsed or refractory T lymphoid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chimeric antigen receptor-T cells (CAR-T) have made breakthroughs in the treatment of B-cell&#xD;
      tumors, especially refractory/relapsed acute B lymphocytes. CD7 is a transmembrane&#xD;
      glycoprotein expressed by T cells and natural killer cells and their precursors; it is also&#xD;
      expressed in &gt;95% of lymphoblastic T-cell leukemias and lymphomas . CD7 was previously&#xD;
      evaluated as a target for immunotoxin-loaded antibodies in patients with T-cell malignancies,&#xD;
      but tumor responses were limited.&#xD;
&#xD;
      Enhancing the potency of CD7-directed cytotoxicity by substituting autologous CAR-T cells for&#xD;
      a monoclonal antibody would augment the efficacy of CD7-targeted therapy in patients with&#xD;
      T-cell malignancies. To prepare CAR7-T cells, CD7 expression is suppressed on autologous T&#xD;
      cells by unique blocking technique, and CD7-negative T cells are transduced with a humanized&#xD;
      anti-CD7-41BB-CD3ζ lentiviral vector.&#xD;
&#xD;
      This is an investigational study. The objectives are to evaluate the safety and efficacy of&#xD;
      CAR7-T cells in patients with CD7+ T-cell malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 7, 2021</start_date>
  <completion_date type="Anticipated">April 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 7, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-related Adverse Events</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate(ORR) of administering CAR7-T cells in Relapsed/Refractory CD7+ T-cell hematological malignancies.</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>ORR will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate(CRR) of administering CAR7-T cells in Relapsed/Refractory CD7+ T-cell hematological malignancies.</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>CRR will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival(PFS) of administering CAR7-T cells in Relapsed/Refractory CD7+ T-cell hematological malignancies.</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>PFS will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR) of administering CAR7-T cells in Relapsed/Refractory CD7+ T-cell hematological malignancies.</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>DOR will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS) of administering CAR7-T cells in Relapsed/Refractory CD7+ T-cell hematological malignancies.</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>OS will be assessed from CAR T cell infusion to death or last follow-up (censored).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>In vivo expansion and survival of CAR7-T cells</measure>
    <time_frame>within 2 years after infusion</time_frame>
    <description>Quantity of CAR copies in bone marrow and peripheral blood will be determined by using quantitative polymerase chain reaction.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>T-Cell Lymphocytic Leukemia</condition>
  <condition>T-Cell Chronic Lymphocytic Leukemia</condition>
  <condition>T Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Fludarabine + Cyclophosphamide + anti-CD7 CAR-T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (250 mg/kg) on day -5, -4, and -3, followed by the infusion of CAR7-T cells with the dose of 0.5×10^6/kg, 1×10^6/kg, 2×10^6/kg and 4×10^6/kg (with an allowance of ±20%) for 3 consecutive days. If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine + Cyclophosphamide + CAR7-T Cells</intervention_name>
    <description>fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0, 1, and 2.</description>
    <arm_group_label>Fludarabine + Cyclophosphamide + anti-CD7 CAR-T Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 18 years;&#xD;
&#xD;
          2. Expected survival over 60 days;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group score 0-2;&#xD;
&#xD;
          4. Diagnosed as T-cell hematologic malignancies (including leukemia and lymphoma)&#xD;
             according to WHO2016 criteria;&#xD;
&#xD;
          5. Patients must relapse or be refractory after at least two lines of therapy.&#xD;
&#xD;
          6. CD7 were positive in bone marrow by immunohistochemistry or flow cytometry at&#xD;
             screening, and one of the following conditions is satisfied: A. No remission was&#xD;
             achieved after at least 2 lines of standard therapy; B. Relapse or progression after&#xD;
             standard treatment; C. Relapse after autologous or allogeneic hematopoietic stem cell&#xD;
             transplantation;&#xD;
&#xD;
          7. Have no fertility requirements or plans for one year since enrolment in this clinical&#xD;
             trial;&#xD;
&#xD;
          8. Patient or his or her legal guardian voluntarily participates in and signs an informed&#xD;
             consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Complicated with central system leukemia/lymphoma;&#xD;
&#xD;
          2. Existing or preexisting CNS conditions, such as epileptic seizures, cerebrovascular&#xD;
             ischemia/hemorrhage, dementia, cerebellar disease, or any CNS related autoimmune&#xD;
             disease;&#xD;
&#xD;
          3. Symptomatic heart failure or severe arrhythmias;&#xD;
&#xD;
          4. Symptoms of severe respiratory failure;&#xD;
&#xD;
          5. Complicated with other types of malignant tumors;&#xD;
&#xD;
          6. Serum creatinine and/or urea nitrogen ≥ 1.5 times of normal value;&#xD;
&#xD;
          7. Suffer from sepsis or other uncontrollable infections;&#xD;
&#xD;
          8. Intracranial hypertension or brain consciousness disorder;&#xD;
&#xD;
          9. Severe mental disorders;&#xD;
&#xD;
         10. Have received organ transplantation (excluding bone marrow transplantation);&#xD;
&#xD;
         11. Female patients (fertile patients) had positive blood HCG test;&#xD;
&#xD;
         12. Hepatitis (including hepatitis B and C), AIDS and syphilis were screened positive;&#xD;
&#xD;
         13. Patients with graft-versus-host disease (GVHD) or who require immunosuppressant&#xD;
             treatment;&#xD;
&#xD;
         14. The absolute value of lymphocytes was too low to manufacture CART cells;&#xD;
&#xD;
         15. Other conditions considered inappropriate by the researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heng Mei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heng Mei</last_name>
    <phone>027-8572600</phone>
    <email>hmei@hust.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chenggong Li</last_name>
    <phone>18868112136</phone>
    <email>chenggongli@hust.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Union Hospital, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heng Mei, M.D., Ph.D</last_name>
      <email>hmei@hust.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yinqiang Zhang</last_name>
      <phone>15007101371</phone>
      <email>zyq_107@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Heng Mei, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 Jul 20;130(3):285-296. doi: 10.1182/blood-2017-01-761320. Epub 2017 May 24.</citation>
    <PMID>28539325</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>MEI HENG</investigator_full_name>
    <investigator_title>Proferssor, Cheif Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

